Clemons K V, Stevens D A
Dept. of Medicine, Santa Clara Valley Medical Center, San Jose, CA 95128-2699.
J Med Vet Mycol. 1994;32(4):323-6. doi: 10.1080/02681219480000411.
The new triazole, D0870, was tested for therapeutic efficacy in the treatment of experimental systemic murine coccidioidomycosis. D0870 at 1 or 10 mg kg-1 daily, or 10 or 100 mg kg-1 every other day, and fluconazole at 100 mg kg-1 daily prolonged survival (P < 0.01), but were equivalent to each other. D0870 at 10 mg kg-1 daily or 100 mg kg-1 every other day cured 20 or 30% of mice of residual infection, respectively, and were superior to 100 mg kg-1 of fluconazole daily (P < 0.001). D0870 is approximately 10-fold more active than fluconazole. It is a promising treatment for coccidioidomycosis, which warrants further testing.
新型三唑类药物D0870用于治疗实验性系统性小鼠球孢子菌病的疗效进行了测试。每日1或10 mg/kg的D0870，或隔日10或100 mg/kg的D0870，以及每日100 mg/kg的氟康唑均可延长生存期（P<0.01），但彼此等效。每日10 mg/kg或隔日100 mg/kg的D0870分别治愈了20%或30%残留感染的小鼠，且优于每日100 mg/kg的氟康唑（P<0.001）。D0870的活性约为氟康唑的10倍。它是一种有前景的球孢子菌病治疗药物，值得进一步测试。
